Phase 1 Safety Study of ALRN-5281 in Healthy Subjects
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of a single
dose of ALRN-5281 administered by subcutaneous injection to healthy adult volunteers.